Novartis/Amgen’s migraine drug hits market at lower than expected price
FDA to make decision on Amgen drug tomorrow
Lilly and Alder take on the might of Novartis and Amgen
Troubled generics giant Teva is continuing the heavy pruning of its business and has cut a novel migraine drug from its pipeline.
Aimovig notches up another late-stage trial success
Erenumab under review in US and EU